Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Recent & Breaking News (TSX:ONC)

Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles

Livemoney June 24, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

PR Newswire June 23, 2020

Oncolytics Biotech® Establishes New At-The-Market Facility

Canada NewsWire June 15, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment

PR Newswire June 4, 2020

Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting

Canada NewsWire May 29, 2020

Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting

PR Newswire May 26, 2020

Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

PR Newswire May 14, 2020

Oncolytics Biotech® to Present at the RBC Global Healthcare Conference

PR Newswire May 13, 2020

The Next Great Breakthroughs In Biotech

Livemoney May 8, 2020

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

PR Newswire May 8, 2020

Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights

PR Newswire May 8, 2020

Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting

PR Newswire May 4, 2020

Oncolytics Biotech® Announces Changes to Annual General Meeting

Canada NewsWire April 30, 2020

Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic

Canada NewsWire April 17, 2020

Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer

Canada NewsWire April 2, 2020

IIROC Trade Resumption - ONC

Canada NewsWire March 24, 2020

IIROC Trading Halt - ONC

Canada NewsWire March 24, 2020

Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update

Canada NewsWire March 24, 2020

The Top Healthcare Bullboards: Jan - Mar 2020

Stockhouse Editorial March 23, 2020

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Canada NewsWire March 5, 2020